Correlation Between Krystal Biotech and Xenetic Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Krystal Biotech and Xenetic Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Krystal Biotech and Xenetic Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Krystal Biotech and Xenetic Biosciences, you can compare the effects of market volatilities on Krystal Biotech and Xenetic Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Krystal Biotech with a short position of Xenetic Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Krystal Biotech and Xenetic Biosciences.

Diversification Opportunities for Krystal Biotech and Xenetic Biosciences

0.01
  Correlation Coefficient

Significant diversification

The 3 months correlation between Krystal and Xenetic is 0.01. Overlapping area represents the amount of risk that can be diversified away by holding Krystal Biotech and Xenetic Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xenetic Biosciences and Krystal Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Krystal Biotech are associated (or correlated) with Xenetic Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xenetic Biosciences has no effect on the direction of Krystal Biotech i.e., Krystal Biotech and Xenetic Biosciences go up and down completely randomly.

Pair Corralation between Krystal Biotech and Xenetic Biosciences

Given the investment horizon of 90 days Krystal Biotech is expected to under-perform the Xenetic Biosciences. But the stock apears to be less risky and, when comparing its historical volatility, Krystal Biotech is 1.37 times less risky than Xenetic Biosciences. The stock trades about -0.24 of its potential returns per unit of risk. The Xenetic Biosciences is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  411.00  in Xenetic Biosciences on October 16, 2024 and sell it today you would lose (3.00) from holding Xenetic Biosciences or give up 0.73% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Krystal Biotech  vs.  Xenetic Biosciences

 Performance 
       Timeline  
Krystal Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Krystal Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Xenetic Biosciences 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Xenetic Biosciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, Xenetic Biosciences displayed solid returns over the last few months and may actually be approaching a breakup point.

Krystal Biotech and Xenetic Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Krystal Biotech and Xenetic Biosciences

The main advantage of trading using opposite Krystal Biotech and Xenetic Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Krystal Biotech position performs unexpectedly, Xenetic Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will offset losses from the drop in Xenetic Biosciences' long position.
The idea behind Krystal Biotech and Xenetic Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance